SK68597A3 - Kit for osteoporosis treatment cycle - Google Patents
Kit for osteoporosis treatment cycle Download PDFInfo
- Publication number
- SK68597A3 SK68597A3 SK685-97A SK68597A SK68597A3 SK 68597 A3 SK68597 A3 SK 68597A3 SK 68597 A SK68597 A SK 68597A SK 68597 A3 SK68597 A3 SK 68597A3
- Authority
- SK
- Slovakia
- Prior art keywords
- tiludronic acid
- nutritional supplement
- pharmaceutically acceptable
- acceptable salts
- calcium
- Prior art date
Links
- 208000001132 Osteoporosis Diseases 0.000 title claims abstract description 23
- 238000011282 treatment Methods 0.000 title abstract description 17
- DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 claims abstract description 47
- 229960005324 tiludronic acid Drugs 0.000 claims abstract description 46
- 150000003839 salts Chemical class 0.000 claims abstract description 39
- 239000011575 calcium Substances 0.000 claims abstract description 26
- 239000012453 solvate Substances 0.000 claims abstract description 26
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 17
- 235000015872 dietary supplement Nutrition 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 22
- KDVKAYPVWJFARG-UHFFFAOYSA-J tetrasodium;[(4-chlorophenyl)sulfanyl-[hydroxy(oxido)phosphoryl]methyl]-hydroxyphosphinate;hydrate Chemical compound O.[Na+].[Na+].[Na+].[Na+].OP([O-])(=O)C(P(O)([O-])=O)SC1=CC=C(Cl)C=C1.OP([O-])(=O)C(P(O)([O-])=O)SC1=CC=C(Cl)C=C1 KDVKAYPVWJFARG-UHFFFAOYSA-J 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 5
- 210000000988 bone and bone Anatomy 0.000 claims description 4
- -1 disodium tiludronate monohydrate Chemical class 0.000 claims description 4
- 235000005911 diet Nutrition 0.000 claims description 2
- 230000037213 diet Effects 0.000 claims description 2
- BWAUQTFFVCLSOS-UHFFFAOYSA-N sodiosodium hydrate Chemical compound O.[Na].[Na] BWAUQTFFVCLSOS-UHFFFAOYSA-N 0.000 claims description 2
- 150000004682 monohydrates Chemical class 0.000 claims 4
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract description 9
- 230000002265 prevention Effects 0.000 abstract description 6
- 239000000203 mixture Substances 0.000 description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 150000004663 bisphosphonates Chemical class 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 229940122361 Bisphosphonate Drugs 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 4
- 159000000007 calcium salts Chemical class 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical class C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical class [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229960000913 crospovidone Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 229920000523 polyvinylpolypyrrolidone Chemical class 0.000 description 3
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- SKUHWSDHMJMHIW-UHFFFAOYSA-L disodium;[(4-chlorophenyl)sulfanyl-[hydroxy(oxido)phosphoryl]methyl]-hydroxyphosphinate Chemical compound [Na+].[Na+].OP([O-])(=O)C(P(O)([O-])=O)SC1=CC=C(Cl)C=C1 SKUHWSDHMJMHIW-UHFFFAOYSA-L 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 229940050410 gluconate Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- JOOXCMJARBKPKM-UHFFFAOYSA-M 4-oxopentanoate Chemical compound CC(=O)CCC([O-])=O JOOXCMJARBKPKM-UHFFFAOYSA-M 0.000 description 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
- 241000220479 Acacia Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004135 Bone phosphate Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- QHFQAJHNDKBRBO-UHFFFAOYSA-L calcium chloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].[Cl-].[Ca+2] QHFQAJHNDKBRBO-UHFFFAOYSA-L 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- PWKNEBQRTUXXLT-ZBHRUSISSA-L calcium lactate gluconate Chemical compound [Ca+2].CC(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O PWKNEBQRTUXXLT-ZBHRUSISSA-L 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Chemical class 0.000 description 1
- 229920002678 cellulose Chemical class 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- CEGDCUKGIQDKKW-UHFFFAOYSA-L disodium;2-hydroxypropane-1,2,3-tricarboxylic acid;carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O.OC(=O)CC(O)(C(O)=O)CC(O)=O CEGDCUKGIQDKKW-UHFFFAOYSA-L 0.000 description 1
- OKBPCTLSPGDQBO-UHFFFAOYSA-L disodium;dichloride Chemical compound [Na+].[Na+].[Cl-].[Cl-] OKBPCTLSPGDQBO-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 229940058352 levulinate Drugs 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- LUDDKAMNGZPYBT-GTDRIFFSSA-M sodium dodecyl sulfate (2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O LUDDKAMNGZPYBT-GTDRIFFSSA-M 0.000 description 1
- CLJTZNIHUYFUMR-UHFFFAOYSA-M sodium;hydrogen carbonate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].OC([O-])=O.OC(=O)CC(O)(C(O)=O)CC(O)=O CLJTZNIHUYFUMR-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 229940019375 tiludronate Drugs 0.000 description 1
- 229940032666 tiludronate disodium Drugs 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9414630A FR2727629A1 (fr) | 1994-12-06 | 1994-12-06 | Trousse pour cycle de traitement de l'osteoporose |
| PCT/FR1995/001596 WO1996017616A1 (fr) | 1994-12-06 | 1995-12-05 | Trousse pour cycle de traitement de l'osteoporose |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK68597A3 true SK68597A3 (en) | 1997-11-05 |
Family
ID=9469504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK685-97A SK68597A3 (en) | 1994-12-06 | 1995-12-05 | Kit for osteoporosis treatment cycle |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP0797444A1 (enExample) |
| JP (1) | JPH10509729A (enExample) |
| KR (1) | KR980700083A (enExample) |
| CN (1) | CN1168634A (enExample) |
| AR (1) | AR002946A1 (enExample) |
| AU (1) | AU4307396A (enExample) |
| BR (1) | BR9509961A (enExample) |
| CA (1) | CA2207028A1 (enExample) |
| CZ (1) | CZ175397A3 (enExample) |
| FI (1) | FI972383A0 (enExample) |
| FR (1) | FR2727629A1 (enExample) |
| HU (1) | HUT77382A (enExample) |
| IL (1) | IL116168A0 (enExample) |
| MA (1) | MA23737A1 (enExample) |
| NO (1) | NO972558L (enExample) |
| PL (1) | PL320564A1 (enExample) |
| SK (1) | SK68597A3 (enExample) |
| TR (1) | TR199501530A1 (enExample) |
| WO (1) | WO1996017616A1 (enExample) |
| ZA (1) | ZA9510184B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5994329A (en) | 1997-07-22 | 1999-11-30 | Merck & Co., Inc. | Method for inhibiting bone resorption |
| US6432932B1 (en) | 1997-07-22 | 2002-08-13 | Merck & Co., Inc. | Method for inhibiting bone resorption |
| SI1506041T1 (sl) | 2002-05-10 | 2008-02-29 | Hoffmann La Roche | Ibandronska kislina za zdravljenje in preprecevanje osteoporoze |
| WO2004056373A1 (en) * | 2002-12-20 | 2004-07-08 | F. Hoffmann-La Roche Ag | High dose ibandronate formulation |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3583887D1 (de) * | 1984-04-30 | 1991-10-02 | Procter & Gamble | Ausruestung fuer die behandlung der osteoporose. |
| US4761406A (en) * | 1985-06-06 | 1988-08-02 | The Procter & Gamble Company | Regimen for treating osteoporosis |
| DK0648120T3 (da) * | 1992-06-30 | 1998-01-19 | Procter & Gamble Pharma | Anvendelse af phosphonater til behandling af osteoporose |
| FR2694558B1 (fr) * | 1992-08-05 | 1994-10-28 | Sanofi Elf | Monohydrate du sel disodique de l'acide 4-chlorophénylthiométhylène bisphosphonique, sa préparation, les compositions pharmaceutiques en contenant. |
-
1994
- 1994-12-06 FR FR9414630A patent/FR2727629A1/fr active Granted
-
1995
- 1995-11-28 IL IL11616895A patent/IL116168A0/xx unknown
- 1995-11-30 ZA ZA9510184A patent/ZA9510184B/xx unknown
- 1995-12-04 MA MA24086A patent/MA23737A1/fr unknown
- 1995-12-04 TR TR95/01530A patent/TR199501530A1/xx unknown
- 1995-12-05 AU AU43073/96A patent/AU4307396A/en not_active Abandoned
- 1995-12-05 SK SK685-97A patent/SK68597A3/sk unknown
- 1995-12-05 JP JP8517359A patent/JPH10509729A/ja not_active Ceased
- 1995-12-05 WO PCT/FR1995/001596 patent/WO1996017616A1/fr not_active Ceased
- 1995-12-05 AR ARP950100438A patent/AR002946A1/es unknown
- 1995-12-05 CN CN95196670A patent/CN1168634A/zh active Pending
- 1995-12-05 CA CA002207028A patent/CA2207028A1/en not_active Abandoned
- 1995-12-05 HU HU9702097A patent/HUT77382A/hu unknown
- 1995-12-05 EP EP95941761A patent/EP0797444A1/fr not_active Withdrawn
- 1995-12-05 PL PL95320564A patent/PL320564A1/xx unknown
- 1995-12-05 CZ CZ971753A patent/CZ175397A3/cs unknown
- 1995-12-05 FI FI972383A patent/FI972383A0/fi not_active Application Discontinuation
- 1995-12-05 KR KR1019970703784A patent/KR980700083A/ko not_active Withdrawn
- 1995-12-05 BR BR9509961A patent/BR9509961A/pt not_active Application Discontinuation
-
1997
- 1997-06-05 NO NO972558A patent/NO972558L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TR199501530A1 (tr) | 1996-10-21 |
| BR9509961A (pt) | 1997-11-25 |
| MA23737A1 (fr) | 1996-07-01 |
| FR2727629B1 (enExample) | 1997-02-28 |
| FI972383A7 (fi) | 1997-06-05 |
| ZA9510184B (en) | 1996-06-11 |
| IL116168A0 (en) | 1996-01-31 |
| CN1168634A (zh) | 1997-12-24 |
| CZ175397A3 (en) | 1997-10-15 |
| PL320564A1 (en) | 1997-10-13 |
| JPH10509729A (ja) | 1998-09-22 |
| WO1996017616A1 (fr) | 1996-06-13 |
| EP0797444A1 (fr) | 1997-10-01 |
| CA2207028A1 (en) | 1996-06-13 |
| FI972383L (fi) | 1997-06-05 |
| FI972383A0 (fi) | 1997-06-05 |
| HUT77382A (hu) | 1998-04-28 |
| NO972558L (no) | 1997-08-05 |
| AU4307396A (en) | 1996-06-26 |
| KR980700083A (ko) | 1998-03-30 |
| FR2727629A1 (fr) | 1996-06-07 |
| NO972558D0 (no) | 1997-06-05 |
| AR002946A1 (es) | 1998-05-27 |
| MX9704105A (es) | 1997-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2133084E (pt) | Formulação farmacêutica que compreende compostos de lantânio | |
| EP0521388B1 (de) | Verfahren zur Herstellung einer pharmazeutischen Zubereitung mit wenigstens zwei verschiedenen Wirkstoffen und Verwendung einer solchen Zubereitung | |
| GB2195246A (en) | Sustained release fluoride and calcium composition | |
| EP0304987A2 (en) | Novel calcium supplements | |
| RU2261098C2 (ru) | Перорально распадающаяся композиция, содержащая миртазапин | |
| Petrere et al. | Developmental toxicity studies in mice, rats, and rabbits with the anticonvulsant gabapentin | |
| US4859467A (en) | Sustained release fluoride composition | |
| SK121699A3 (en) | Stable solid preparation containing vitamin d3 and tricalcium phosphate | |
| EP1651191B1 (en) | Effervescent pharmaceutical compositions containing vitamin d, calcium and phospate and their therapeutic use | |
| US5013728A (en) | Composition for treating osteoporosis and hormonal imbalance | |
| JPS5938203B2 (ja) | 補酵素ｑを主成分とする脳循環障害治療剤 | |
| SK68597A3 (en) | Kit for osteoporosis treatment cycle | |
| US6696083B1 (en) | Vitamin/nutrient dosage regimentation | |
| US20040121025A1 (en) | Oral composition for the treatment and prevention of bone loss | |
| US5932252A (en) | Method and composition for treatment of osteoporosis | |
| DE20321698U1 (de) | Medikament zur Erhöhung der Bioverfügbarkeit von Alendronat oder einem anderen Bisphosphonat durch Verabreichen einer Vordosis eines Vitamin-D-Derivats | |
| CA2219354A1 (en) | Prevention of tooth loss by the administration of alendronate or its salts | |
| US4517309A (en) | Method for the treatment of calcifying pancreatitis | |
| US9623066B2 (en) | Compositions and methods to inhibit kidney stone growth | |
| MXPA97004105A (en) | Set for use in a therapeutic treatment cycle of osteoporo | |
| RU2273492C1 (ru) | Композиция для профилактики и лечения болезней, вызываемых дефицитом кальция (варианты) | |
| RU2278667C2 (ru) | Состав, регулирующий метаболические процессы, и способ его получения | |
| CN119607012A (zh) | 舞茸多糖d组分或其衍生物在制备抗精神分裂症的药物中的应用 | |
| EP0691814B1 (en) | Method and composition for treatment of osteoporosis | |
| RU2273493C1 (ru) | Композиция для профилактики и лечения болезней, вызываемых дефицитом кальция (варианты) |